• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞周期蛋白依赖性激酶4的表达对于神经诱导的乳腺肿瘤发生至关重要。

Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.

作者信息

Reddy Haritha K D L, Mettus Richard V, Rane Sushil G, Graña Xavier, Litvin Judith, Reddy E Premkumar

机构信息

Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.

出版信息

Cancer Res. 2005 Nov 15;65(22):10174-8. doi: 10.1158/0008-5472.CAN-05-2639.

DOI:10.1158/0008-5472.CAN-05-2639
PMID:16288002
Abstract

Previous work has shown that cyclin D1 expression is required for neu- and ras-induced, but not wnt- or c-myc-induced, breast tumorigenesis in mice. Although cyclin D1 binds and activates cyclin-dependent kinase 4 (Cdk4), thereby mediating activation of a program of E2F-dependent gene expression, it has been suggested that the oncogenic activities of cyclin D1 are independent of Cdk4. To determine whether Cdk4 expression is required for breast tumorigenesis in mice, we have generated compound mice ectopically expressing the neu or wnt oncogenes in the mammary glands of wild-type and Cdk4-/- mice. Our results show that Cdk4 expression is required for efficient neu-induced tumorigenesis but is dispensable for wnt-induced breast tumorigenesis. In contrast to results previously observed in the mammary glands of cyclin D1-/- virgin females, our results show defects in mammary gland development in Cdk4-/- virgin females, suggesting differences in compensatory mechanisms in the absence of either subunit of the cyclin D1/Cdk4 complex. These results suggest that drugs targeted to inhibit Cdk4 activities could be developed to specifically treat certain breast tumors as Cdk4 is not essential for viability.

摘要

先前的研究表明,细胞周期蛋白D1的表达是neu和ras诱导的小鼠乳腺肿瘤发生所必需的,但不是wnt或c-myc诱导的乳腺肿瘤发生所必需的。虽然细胞周期蛋白D1结合并激活细胞周期蛋白依赖性激酶4(Cdk4),从而介导E2F依赖性基因表达程序的激活,但有人提出细胞周期蛋白D1的致癌活性独立于Cdk4。为了确定Cdk4的表达是否是小鼠乳腺肿瘤发生所必需的,我们构建了在野生型和Cdk4基因敲除小鼠的乳腺中异位表达neu或wnt癌基因的复合小鼠。我们的结果表明,Cdk4的表达是有效的neu诱导的肿瘤发生所必需的,但对于wnt诱导的乳腺肿瘤发生是可有可无的。与先前在细胞周期蛋白D1基因敲除处女雌鼠乳腺中观察到的结果相反,我们的结果显示Cdk4基因敲除处女雌鼠的乳腺发育存在缺陷,这表明在细胞周期蛋白D1/Cdk4复合物任一亚基缺失时,补偿机制存在差异。这些结果表明,由于Cdk4对生存力不是必需的,可以开发靶向抑制Cdk4活性的药物来特异性治疗某些乳腺肿瘤。

相似文献

1
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.细胞周期蛋白依赖性激酶4的表达对于神经诱导的乳腺肿瘤发生至关重要。
Cancer Res. 2005 Nov 15;65(22):10174-8. doi: 10.1158/0008-5472.CAN-05-2639.
2
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.细胞周期蛋白D1依赖性激酶活性在小鼠发育和乳腺肿瘤发生中的作用
Cancer Cell. 2006 Jan;9(1):13-22. doi: 10.1016/j.ccr.2005.12.019.
3
Is Cyclin D1-CDK4 kinase a bona fide cancer target?细胞周期蛋白D1 - 细胞周期蛋白依赖性激酶4激酶是一个真正的癌症靶点吗?
Cancer Cell. 2006 Jan;9(1):2-4. doi: 10.1016/j.ccr.2005.12.026.
4
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.通过p110α的膜定位激活磷脂酰肌醇3激酶会使乳腺易发生肿瘤转化。
Cancer Res. 2008 Dec 1;68(23):9643-53. doi: 10.1158/0008-5472.CAN-08-1539.
5
Requirement for CDK4 kinase function in breast cancer.乳腺癌中CDK4激酶功能的需求。
Cancer Cell. 2006 Jan;9(1):23-32. doi: 10.1016/j.ccr.2005.12.012.
6
Specific protection against breast cancers by cyclin D1 ablation.通过细胞周期蛋白D1缺失对乳腺癌的特异性保护作用。
Nature. 2001 Jun 28;411(6841):1017-21. doi: 10.1038/35082500.
7
Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice.Src激酶在Neu诱导的肿瘤发生中的作用:利用Csk同源激酶转基因小鼠挑战传统模式
Cancer Res. 2006 Jun 1;66(11):5757-62. doi: 10.1158/0008-5472.CAN-05-3536.
8
Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.p53肿瘤抑制基因的失活在涎腺肿瘤发生过程中与c-neu癌基因协同作用。
Oncogene. 2001 Mar 22;20(12):1445-54. doi: 10.1038/sj.onc.1204222.
9
p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.p130Cas作为乳腺上皮细胞增殖、存活及HER2-neu癌基因依赖性乳腺肿瘤发生的新型调节因子。
Cancer Res. 2006 May 1;66(9):4672-80. doi: 10.1158/0008-5472.CAN-05-2909.
10
Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.乳腺靶向表达人皮层肌动蛋白的转基因小鼠不会发生(癌前)乳腺肿瘤:在MMTV-皮层肌动蛋白和MMTV-皮层肌动蛋白/细胞周期蛋白D1双转基因小鼠中的研究。
BMC Cancer. 2006 Mar 14;6:58. doi: 10.1186/1471-2407-6-58.

引用本文的文献

1
CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer.细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂与放疗协同作用,可重塑肿瘤微环境,并增强抗程序性死亡受体配体1(PD-L1)免疫疗法在三阴性乳腺癌中的抗肿瘤效果。
J Biomed Sci. 2025 Aug 20;32(1):79. doi: 10.1186/s12929-025-01173-3.
2
The deubiquitinase USP7 stabilizes HER2 expression and promotes breast cancer progression.去泛素化酶USP7可稳定HER2表达并促进乳腺癌进展。
Neoplasia. 2025 Aug;66:101192. doi: 10.1016/j.neo.2025.101192. Epub 2025 Jun 4.
3
Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report.
曲妥珠单抗、来曲唑、阿贝西利和戈舍瑞林联合作为HER2阳性和激素受体阳性转移性乳腺癌一线治疗的持久且显著反应:一例报告
Case Rep Oncol. 2025 Jan 16;18(1):130-136. doi: 10.1159/000542926. eCollection 2025 Jan-Dec.
4
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer.雌激素受体阳性乳腺癌中的细胞周期蛋白依赖性激酶4/6抑制剂耐药性
Adv Exp Med Biol. 2025;1464:475-493. doi: 10.1007/978-3-031-70875-6_23.
5
Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway.细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂在激素受体阳性且人表皮生长因子受体2(HER2)阴性乳腺癌中的放射增敏作用介导了DNA修复机制和核因子κB(NF-κB)信号通路的下调。
Transl Oncol. 2024 Nov;49:102092. doi: 10.1016/j.tranon.2024.102092. Epub 2024 Aug 16.
6
Novel indolyl 1,2,4-triazole derivatives as potential anti-proliferative agents: studies, synthesis, and biological evaluation.新型吲哚基1,2,4-三唑衍生物作为潜在的抗增殖剂:研究、合成及生物学评价
RSC Med Chem. 2023 Nov 24;15(1):293-308. doi: 10.1039/d3md00524k. eCollection 2024 Jan 25.
7
CDK4: a master regulator of the cell cycle and its role in cancer.细胞周期蛋白依赖性激酶4(CDK4):细胞周期的主要调节因子及其在癌症中的作用。
Genes Cancer. 2022 Aug 25;13:21-45. doi: 10.18632/genesandcancer.221. eCollection 2022.
8
CDK4 and CDK6 kinases: From basic science to cancer therapy.CDK4 和 CDK6 激酶:从基础科学到癌症治疗。
Science. 2022 Jan 14;375(6577):eabc1495. doi: 10.1126/science.abc1495.
9
Role of hydrogen sulfide donors in cancer development and progression.硫化氢供体在癌症发展和进展中的作用。
Int J Biol Sci. 2021 Jan 1;17(1):73-88. doi: 10.7150/ijbs.47850. eCollection 2021.
10
FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells.FUCCI实时细胞周期成像作为设计改进癌症治疗方法的指南:靶向静止化疗耐药癌细胞的创新策略综述
Cancers (Basel). 2020 Sep 17;12(9):2655. doi: 10.3390/cancers12092655.